Phases, active trials: Phase 1: 46, Phase 1/2: 25, Phase 2: 68, Phase 2/3: 2, Phase 3: 87, Phase 4: 24, No phase listed: 115
Novartis has a diversified late-stage pipeline spanning oncology, ophthalmology, cardiovascular, and immunology. Their radioligand therapy (RLT) franchise, anchored by Lutathera and Pluvicto (lutetium PSMA-617), has established Novartis as the leader in targeted radiotherapy for solid tumors. In breast cancer, Kisqali (ribociclib) continues expanding into new settings against CDK4/6 inhibitor competitors. Kymriah pioneered the CAR-T category, and Novartis continues investing in next-generation cell therapies. Their ophthalmology pipeline (Luxturna gene therapy, complement inhibitors for geographic atrophy) represents a major growth vector.
- Oncology (radioligand, CDK4/6, CAR-T)
- Ophthalmology / gene therapy
- Cardiovascular
- Immunology / inflammation
- Neuroscience
- Kisqali (ribociclib): HR+ breast cancer CDK4/6 inhibitor
- Pluvicto (lutetium-177 PSMA): metastatic prostate cancer
- Kymriah (tisagenlecleucel): CAR-T lymphoma/leukemia
- Cosentyx (secukinumab): IL-17A, psoriasis/ankylosing spondylitis
- Iptacopan: complement Factor B, IgA nephropathy
- Scemblix (asciminib): BCR-ABL1 CML
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| CAR-T Long Term Follow Up (LTFU) Study NCT02445222 | Primary completion moved at least 3 years 1 month later Enrollment reduced 21% | Recruiting |
36 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in… NCT06894511 | Nov 17, 2026 · Estimated | Phase 2 |
26 more on the Completions page. See the calendar →
Monitor the Novartis pipeline daily
Get a daily digest when Novartis registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Hidradenitis Suppurativa | 12 |
| Breast Cancer | 11 |
| Chronic Spontaneous Urticaria | 10 |
| Multiple Sclerosis | 10 |
| Relapsing Multiple Sclerosis | 8 |
| Atherosclerotic Cardiovascular Disease | 6 |
| Immunoglobulin A Nephropathy | 6 |
| Asthma | 5 |
Novartis regularly initiates combination trials for Kisqali and Pluvicto in new patient populations. Their radioligand therapy pipeline expansion, beyond PSMA into SSTR2 and other targets, is one of the most watched programs in oncology BD.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Novartis's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Novartis may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Novartis pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer NCT07908667 | Recruiting | Recruitment opened | 2026-11-14 |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) NCT07357727 | Recruiting | Trial sites expanded: 163 → 168 locations | 2026-11-14 |
| An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in… NCT06894511 | Active, Not Recruiting | Study completion pushed from Oct 15, 2026 to Nov 17, 2026 | 2026-11-13 |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib NCT06401356 | Recruiting | Interventions modified | 2026-11-13 |
| Roll-over Study to Collect and Assess Long-term Safety of Everolimus in… NCT02962414 | Active, Not Recruiting | Study completion pushed from Dec 30, 2026 to Feb 26, 2027 | 2026-11-13 |
Each trial page shows every change DataLookout has recorded for that trial.